These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1592543)

  • 1. Pharmaceutical and biopharmaceutical quality of a sustained release carbamazepine preparation: a contribution to quality assurance.
    Grunwald F; Czaja J; Düsing R; Schulz HU
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):160-6. PubMed ID: 1592543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigations into the relative bioavailability of carbamazepine after single oral administration of three test batches of a carbamazepine-containing sustained release formulation in healthy subjects.
    Schulz HU; Düsing R; Grunwald F; Czaja J; Lührmann B; Frecks HJ
    Int J Clin Pharmacol Ther Toxicol; 1992 Apr; 30(4):139-44. PubMed ID: 1572759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the bioequivalence of two carbamazepine sustained-release formulations in healthy subjects.
    Schulz HU; Düsing R; Lührmann B; Frercks HJ
    Int J Clin Pharmacol Ther Toxicol; 1992 Oct; 30(10):410-4. PubMed ID: 1446959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability study of two carbamazepine containing sustained release formulations after multiple oral dose administration.
    Wangemann M; Retzow A; Evers G; Mazur D; Schug B; Blume H
    Arzneimittelforschung; 1998 Dec; 48(12):1131-7. PubMed ID: 9893926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Carbamazepine: the bioavailability of 4 oral pharmaceutical products].
    Saavedra I; Passalacqua A; Chávez H; Biagini L; Galdames D
    Rev Med Chil; 1990 Oct; 118(10):1123-8. PubMed ID: 2152631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bioavailability of theophylline in a new oral sustained-release preparation (author's transl)].
    Schneider GF; Heese GU; Huber HJ; Janzen N; Jünger H; Moser C; Stanislaus F
    Arzneimittelforschung; 1981; 31(9):1489-97. PubMed ID: 7197962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation.
    Konsil J; Dechasathian S; Mason DH; Stevens RE
    J Pharm Pharm Sci; 2002; 5(2):169-75. PubMed ID: 12207869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg.
    Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP
    J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of food on the bioavailability of a carbamazepine slow-release formulation.
    Retzow A; Schürer M; Schulz HU
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):557-60. PubMed ID: 9455713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations.
    Wolf P; May T; Tiska G; Schreiber G
    Arzneimittelforschung; 1992 Mar; 42(3):284-8. PubMed ID: 1497685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biopharmaceutical characterization of carbamazepine immediate release tablets. In vitro-in vivo comparison.
    Homsek I; Parojcic J; Cvetkovic N; Popadic D; Djuric Z
    Arzneimittelforschung; 2007; 57(8):511-6. PubMed ID: 17915636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system.
    Dokoumetzidis A; Macheras P
    Int J Pharm; 2006 Sep; 321(1-2):1-11. PubMed ID: 16920290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the absorption from three ibuprofen formulations.
    Regazzi BM; Rondanelli R; Ciaroelli L; Bartoli AL; Rampini A
    Int J Clin Pharmacol Res; 1986; 6(6):469-73. PubMed ID: 3804520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of absorption rate and bioavailability of two brands of carbamazepine.
    Revankar SN; Desai ND; Bhatt AD; Bolar HV; Sane SP; Gupta C; Kamat DV
    J Assoc Physicians India; 1999 Jul; 47(7):699-702. PubMed ID: 10778590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability and central side effects of different carbamazepine tablets.
    Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23(4):226-32. PubMed ID: 3997307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of an in vitro absorption model system for predicting sustained release of verapamil.
    Neubert R; Fahr F; Mäder C; Lücke L; Fries G; Rostock G
    Arzneimittelforschung; 1992 Sep; 42(9):1098-100. PubMed ID: 1445475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability and pharmacokinetic properties of 2 sustained-release formulations of diclofenac sodium, Voltaren vs inflaban: effect of food on inflaban bioavailability.
    Zmeili S; Hasan M; Najib N; Sallam E; Deleq S; Shubair M
    Int J Clin Pharmacol Ther; 1996 Dec; 34(12):564-70. PubMed ID: 8996854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative evaluation of pharmacokinetics of conventional and slow-release carbamazepine formulation in newly treated patients of epilepsy: a random evaluation.
    Nag D; Garg RK; Agarwal A
    J Assoc Physicians India; 1998 Feb; 46(2):185-8. PubMed ID: 11273108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PK/PD modelling of high-dose diltiazem--absorption-rate dependency of the hysteresis loop.
    Luckow V; Della Paschoa O
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):418-25. PubMed ID: 9352390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biological availability of potassium from a sustained release preparation].
    Müller A; Thoma M; Renker H
    Schweiz Med Wochenschr; 1976 Jan; 106(1):27-30. PubMed ID: 1251146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.